Navigation Links
ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
Date:1/24/2008

Changes in prescribing behavior appear inconsistent with ACC statements on

ENHANCE study results

MOUNT LAUREL, N.J., Jan. 24 /PRNewswire/ -- ImpactRx, Inc., the pioneering force in measuring the impact of pharmaceutical promotion on physicians' prescribing behavior, has released data showing a sharp drop in prescribing Zetia and Vytorin since Merck / Schering-Plough's release of the ENHANCE study results on January 14. That study was designed to determine if ezetimibe (Zetia) and simvastatin used in combination was more effective than simvastatin alone in slowing the growth of plaque in the carotid artery. There was no statistically significant difference between treatment groups on the primary endpoint: mean change in the intima-media thickness (IMT) measured at three sites in the carotid arteries.

In the past week, primary care physicians' usage of Vytorin, the combination of Zetia and simvastatin, has declined from 15% of new treatment decisions to 5%. Among cardiologists, the decline has been less severe, from 15% of new treatment decisions to around 8%. Zetia's share of this treatment population has declined from about 8% to less than 5% among both PCPs and cardiologists. Switching from Vytorin and Zetia is driving this trend, along with less initial use among patients naive to drug therapy. As of yesterday, it appears this decline may have begun to stabilize.

"The reaction among physicians and patients is a bit puzzling," said John Kain, Vice President of Marketing at ImpactRx. "The American College of Cardiology released a statement recommending 'that major clinical decisions not be made on the basis of the ENHANCE study alone'. Both medicines were generally well tolerated and the overall incidence rates of cardiac events were nearly identical between both treatment groups, it concluded. The College specifically noted, 'There should be no reason for patients to panic'," Kain continued, "but the data certainly indicate a change in attitude towards these drugs has occurred."

"ImpactRx collects information directly from a panel of high prescribing physicians," noted Kain. "By focusing on physicians' new written prescriptions (NWRx), defined as drug therapy for newly diagnosed patients, add-on therapy or brand switches, our research is more sensitive and typically leads dispensed (NRx) trend changes. Our methodology provides unique insight, especially during periods of rapid change in prescribing behavior driven by market events."

Kain continued, "As always, ImpactRx will be monitoring prescribing changes closely. The incidence of drug switching in this category has risen dramatically since ENHANCE was released, with simvastatin now garnering two- thirds of those changes from Vytorin. Yet patient requests have increased only moderately. We'll be conducting research among physicians to explore their current attitudes towards Zetia and Vytorin and to understand their concerns regarding the latest clinical data."

About ImpactRx

Founded in October 2000, the physician networks of ImpactRx are the source of an unprecedented intelligence capability for tracking the promotional initiatives of the pharmaceutical industry and for measuring their impact on physician prescribing behavior. Based in Mount Laurel, New Jersey, ImpactRx is a private company with investment financing provided by Mediphase Venture Partners (http://www.mediphaseventure.com), Oxford Bioscience Partners (http://www.oxbio.com), Merck Capital Ventures (http://www.merckcapitalventures.com) and 3i Group (http://www.3i.com).

CONTACT:

John Kain

Vice President, Marketing

ImpactRx, Inc.

856-273-0221, ext. 141

jkain@impactrx.com


'/>"/>
SOURCE ImpactRx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor
2. ORTHO EVRA(R) Prescribing Information Updated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):